790 related articles for article (PubMed ID: 35265074)
1. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ; Mashouf LA; Lim M
Front Immunol; 2022; 13():817296. PubMed ID: 35265074
[TBL] [Abstract][Full Text] [Related]
2. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
3. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
4. CAR T-cells to treat brain tumors.
Guzman G; Pellot K; Reed MR; Rodriguez A
Brain Res Bull; 2023 May; 196():76-98. PubMed ID: 36841424
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
6. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
7. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
9. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
10. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
11. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract][Full Text] [Related]
12. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
[TBL] [Abstract][Full Text] [Related]
13. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
Kringel R; Lamszus K; Mohme M
Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
16. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
17. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
18. CAR T-Cell Therapies in Glioblastoma: A First Look.
Migliorini D; Dietrich PY; Stupp R; Linette GP; Posey AD; June CH
Clin Cancer Res; 2018 Feb; 24(3):535-540. PubMed ID: 29158268
[TBL] [Abstract][Full Text] [Related]
19. CAR-T cells for pediatric brain tumors: Present and future.
Leruste A; Beccaria K; Doz F
Bull Cancer; 2021 Oct; 108(10S):S109-S116. PubMed ID: 34920793
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]